Legend Biotech (LEGN) Receivables - Other (2019 - 2025)

Legend Biotech (LEGN) has 7 years of Receivables - Other data on file, last reported at $1.2 million in Q3 2025.

• Quarterly Receivables - Other fell 38.71% year-over-year to $1.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $1.2 million (down 38.71% YoY) and the FY2024 annual result came in at $780000.0, down 1.27% from the prior year.
• Receivables - Other grew to $1.2 million in Q3 2025, from $1.0 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $50.0 million in Q4 2021 to a low of $46000.0 in Q2 2021.
• A 5-year average of $12.0 million and a median of $1.1 million in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2022 — Receivables - Other sank 98.1% — and 2024, when it decreased 1.27%.
• Tracing LEGN's Receivables - Other over 5 years: stood at $50.0 million in 2021, then slumped by 98.1% to $948000.0 in 2022, then fell by 16.67% to $790000.0 in 2023, then retreated by 1.27% to $780000.0 in 2024, then soared by 49.62% to $1.2 million in 2025.
• The last three Receivables - Other figures came in at $1.2 million (Q3 2025), $1.0 million (Q2 2025), and $954000.0 (Q1 2025), per Business Quant data.